medigraphic.com
Medicina Universitaria

2008, Number 39

<< Back Next >>

Med Univer 2008; 10 (39)

Mannose-binding lectin on innate immunity

Villarreal AMA, Ortiz LR, Rojas MA, Garza EMA, Suárez GJ

Language: Spanish
References: 35
Page: 102-107
PDF size: 215.89 Kb.


ABSTRACT

Mannose-binding lectin (MBL) is a protein whose gen (MBL 2) is in the long arm of chromosome 10. Low serum concentrations of this protein may be affected by three genetic variants (B, C, and D) in the structural portion of the MBL 2 gen and to additional variations in the promoter region of it, which generate two polymorphic sites (H/L and X/Y). These polymorphisms create diverse haplotypes in some human communities that may increase the susceptibility to infections, generalized lupus erythematous and rheumatoid arthritis. This study reviews the MBL 2 gen polymorphisms and its relation with the health of the affected human populations.


REFERENCES

  1. Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004;199:1295-9.

  2. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency-revisited. Mol Immunol 2003;40:73-84.

  3. Boldt AB, Petzl Erler ML. A new strategy for mannose-binding lectin gene haplotyping. Hum Mutat 2002;19:296-306.

  4. Steffensen R, Hoffmann K, Varming K. Rapid genotyping of MBL2 gene mutations using real-time PCR with fluorescent hybridisation probes. J Immunol Methods 2003;278:191-9.

  5. Dahl M, Tybjaerg Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannosebinding lectin deficiency. J Exp Med 2004;199:1391-9.

  6. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001;2:442-50.

  7. Miller ME, Seals J, Kaye R, Levitsky LC. A familial plasma associated defect of phagocytosis. Lancet 1968;60-63.

  8. Dommett RM, Klein N, Turner MW. Mannose binding lectin in innate immunity: past, present and future. Tissue Antigens 2006;68:193-209.

  9. Garred P, Nielsen MA, Kurtzhals JA, Malhotra R, et al. Mannose- binding lectin is a disease modifier in clinical malaria and may function as opsonin for plasmodium falciparum-infected erythrocytes. Infect Immun 2003;71:5245-53.

  10. Villarreal J, Crosdale D, Ollier W, Hajeer A, et al. Mannose binding lectin and FcgammaRIIa (CD32) polymorphism in spanish systemic lupus erythematosus patients. Rheumatology (Oxford) 2001;40:1009-12.

  11. Stengaard Pedersen K, Thiel S, Gadjeva M, Moller Kristensen M, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003;349:554-60.

  12. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000;343:338-44.

  13. Ambrosio AR. De Messias-Reason IJT. Leishmania (Viannia braziliensis): Interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody- independent defence mechanism. Parasite Immunol 2005;27:333-40.

  14. Juliger S, Kremsner PG, Alpers MP, Reeder JC, Kun JF. Restricted polymorphisms of the mannose-binding lectin gene in a population of Papua New Guinea. Mutat Res 2002;505:87-91.

  15. Larsen F, Madsen HO, Sim RB, Koch C, Garred P. Disease- associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004;279:21302-11.

  16. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 2004;20:327-35.

  17. Best LG, Davidson M, North KE, MacCluer JW, et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in american indians: the strong heart study. Circulation 2004;10:471-5.

  18. Rugonfalvi Kiss S, Endresz V, Madsen HO, Burian K, et al. Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation 2002;106:1071-6.

  19. García Laorden MI, Rúa Figueroa I, Pérez Aciego P, Rodríguez Pérez JC, et al. Mannose binding lectin polymorphisms as a disease-modulating factor in women with systemic lupus erythematosus from canary islands, spain. J Rheumatol 2003;30:740-6.

  20. Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998;199:327-39.

  21. Graudal NA, Garred P, Madsen HO, Svejgaard A, et al. Variant mannose-binding lectin genotypes and outcome in early versus late rheumatoid arthritis: comment on the article by ip et al. Arthritis Rheum 2002;46:555-6.

  22. Jacobsen S, Baslund B, Madsen HO, Tvede N, et al. Mannosebinding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis. J Rheumatol 2002;29:2148-53.

  23. Kruse C, Rosgaard A, Steffensen R, Varming K, et al. Low serum level of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion. Am J Obstet Gynecol 2002;187:1313-20.

  24. Minchinton RM, Dean MM, Clark TR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an australian blood donor population. Scand J Immunol 2002;56:630-41.

  25. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;35:260-7.

  26. Flores Alvarado D, Esquivel Valerio J, Galarza Delgado D, Garza Elizondo MA. Causas de muerte en lupus eritematoso sistémico. Med Universitaria 1998;1:1-6.

  27. Juárez M, Misischia R, Alarcón GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am 2003;29:163-84.

  28. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528-34.

  29. Guzmán J, Cardiel MH, Arce Salinas A, Sánchez Guerrero J, Alarcón Segovia D. Measurement of disease activity in systemic lupus erythematosus. prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.

  30. Hochberg MC. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

  31. Martínez de Villarreal LE, Delgado Enciso I, Valdez Leal R, Ortiz López R, et al. Folate levels and N(5),N(10)-methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: a case-control study. Arch Med Res 2001;32:277-82.

  32. Perales Dávila J, Martínez de Villarreal LE, Triana Saldaña H, Saldívar Rodríguez D, et al. [Folic acid levels, homocysteine and polymorphism of methylenetetrahydrofolate reductase enzyme (MTHFR) in patients with pre-eclampsia and eclampsia]. Ginecol Obstet Mex 2001;69:6-11.

  33. Delgado Enciso I, Martínez Garza SG, Rojas Martínez A, Ortiz-López R, et al. [677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from the northeastern mexico. preliminary results]. Rev Gastroenterol Mex 2001;66:32-37.

  34. Tin SK, Lee LY, Thumboo J, Koh DR, Fong KY. PCR-RFLP genotyping for exon 1 and promoter region mutations of the human mannose binding lectin (MBL-2) gene. J Immunol Methods 2005;303:148-51.

  35. Valdimarsson H, Vikinsdottir T, Bang P, Saevarsdottir S, et al. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol 2004;59:97-102.




2020     |     www.medigraphic.com